Regulatory T cells and cancer: An undesired tolerance

Kidney International

Volumn 86, Issue 1, 2014, Pages 16-18

  Ducloux, Didier ^a,b,c,d  

^a France   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d Plateforme de Biomonitoring   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; CALCINEURIN INHIBITOR; CD31 ANTIGEN; MACROPHAGE DERIVED CHEMOKINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEUROPILIN 1; PROSTAGLANDIN E2; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ANIMAL CELL; B LYMPHOCYTE; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CARCINOGENESIS; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; DENDRITIC CELL; DISEASE SEVERITY; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; KIDNEY TRANSPLANTATION; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR CELL; TUMOR IMMUNITY; ADVERSE EFFECTS; FEMALE; IMMUNOLOGY; MALE; NEOPLASMS;

FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MALE; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84903712906     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.46     Document Type: Note

References (12)

1. Webster AC, Craig JC, Simpson JM et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15,183 recipients. Am J Transplant 2007; 7: 2140-2151. (Pubitemid 47247055)
2. Hope CM, Grace BS, Pilkington KR et al. The immune phenotype may relate to cancer development in kidney transplant recipients. Kidney Int 2014; 86: 175-183.
3. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 2012; 22: 327-334.
4. Nishikawa H, Sakaguchi S. Regulatory T cells in tumour immunity. Int J Cancer 2010; 127: 759-767.
5. Bergmann C, Strauss L, Wang Y et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008; 14: 3706-3715.
6. Zabransky DJ, Nirschl CJ, Durham NM et al. Phenotypic and functional properties of Helios+ regulatory T cells. PLoS One [online] 7: E34547.
7. Malchow S, Leventhal DS, Nishi S et al. Aire-dependent thymic development of tumour-Associated regulatory T cells. Science 2013; 339: 1219-1224.
8. Elkord E, Alcantar-Orozco EM, Dovedi SJ et al. T regulatory cells in cancer: Recent advances and therapeutic potential. Expert Opin Biol Ther 2010; 10: 1573-1586.
9. Carroll RP, Hester J, Wood KJ et al. Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype. Nephrol Dial Transplant 2013; 28: 462-465.
10. Euvrard S, Morelon E, Rostaing L et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329-339.
11. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune response to tumour antigen vaccination by targeting regulatory T cells. Ann NY Acad Sci 2009; 1174: 99-106.
12. Okita R, Yamaguchi Y, Ohara M et al. Targeting of CD4+CD25high cells while preserving CD4+CD25low cells with low-dose chimeric anti-CD25 antibody in adoptive immunotherapy of cancer. Int J Oncol 2009; 34: 563-572.